Oct 17th 2013 - Edison Investment Research today published a report on Diaxonhit SA (ALEHT.L, LSE:ALEHT, LON:ALEHT) entitled "In It Together". In summary, the report says:
Diaxonhit's integration of the Exonhit and InGen BioSciences appears to be making good progress towards the formation of a fully integrated IVD company. Diaxonhit is implementing its strategy of growing its distribution activities using the existing sales organisation by in-licensing proprietary products, adding new exclusive contracts and expanding territories, while accelerating the development of novel diagnostic products. The combination of the two companies' operations should enable cost improvements and a reduction in cash burn.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »